|  |  |  |  |
| --- | --- | --- | --- |
| **Supplementary table 1** Administration of L-asparaginase in two most common treatment protocols among study patients. | | | |
| **Protocol** | **Treatment phase** | **L-asparaginase dose** | **Frequency** |
| **ALL IC - BFM 2009** | *Induction therapy* (standard-risk group, intermediate-risk group, high-risk group) | 5000IU/m²/d | q 3 days / x 9 doses |
|  | *Early intensification* (Protocol I B Augmented: intermediate-riskgroup arm 2 / high-risk group arm 2) | 5000IU/m²/d | q 2 or 3 days / x 12 doses |
|  | *Reinduction therapy* |  |  |
|  | *Protocol II* (standard-risk group, intermediate-risk group, high-risk group) | 10000IU/m²/d | q 3 days / 4 doses |
|  | *HR Therapy* (high-risk group)\*1 |  |  |
|  | Block HR-1' | 25000IU/m² / d | 1 dose |
|  | Block HR-2' | 25000IU/m² / d | 1 dose |
|  | Block HR-3' | 25000IU/m² / d | 1 dose |
|  | *Reinduction therapy* (high-risk group) | 10000IU/m²/d | q 3 days / 4 doses |
| **GBTLI LLA - 2009** |  |  |  |
| *LLA-B* | *Induction therapy* |  |  |
|  | Low-risk group | 5000IU/m²/d | q 3 days / x 8 doses |
|  | High-risk group | 10000IU/m²/d | q 3 days / x 9 doses |
|  | *Intensification therapy* (high-risk group) | 6000IU/m²/d | q 2 or 3 days / x 6 doses |
|  | *Interphase therapy* (high-risk group) | 10000IU/m²/d | q 21 days / x 3 doses |
|  | *Consolidation therapy* |  |  |
|  | Low-risk group | 5000IU/m²/d | q 2 days / 4 doses |
|  | High-risk group | 6000IU/m²/d | q 2 or 3 days / x 6 doses |
| *LLA-T* | *Induction therapy* | 10000IU/m²/d | q 2 days / 9 doses |
|  | *Intensification therapy* | 6000IU/m²/d | q 2 or 3 days / x 6 doses |
|  | *Interphase therapy* | 10000IU/m²/d | q 21 days / x 3 doses |
|  | *Consolidation therapy* | 6000IU/m²/d | q 2 or 3 days / x 6 doses |
| \*1 HR blocks given twice, with a total of 6 blocks | | | |
| Adapted from ALL IC-BFM 2009 and GBTLI LLA-2009. | | | |